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ABSTRACT
Crohn’s disease (CD) is a major form of inflammatory bowel disease characterized by transmural 
inflammation along the alimentary tract. Changes in the microbial composition and reduction in 
species diversity are recognized as pivotal hallmarks in disease dynamics, challenging the gut 
barrier function and shaping a pathological immune response in genetically influenced subjects. 
The purpose of this review is to delve into the modification of the gut microbiota cluster network 
during CD progression and to discuss how this shift compromises the gut barrier integrity, granting 
the translocation of microbes and their products. We then complete the scope of the review by 
retracing gut microbiota dysbiosis interactions with the main pathophysiologic factors of CD, 
starting from the host’s genetic background to the immune inflammatory and fibrotic processes, 
providing a standpoint on the lifestyle/exogenous factors and the potential benefits of targeting 
a specific gut microbiota.
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1. Dysbiosis and bacterial translocation in CD
The intraindividual intestinal microbiota profile is 
extremely diverse and relatively stable over years 
with some minor reversible disruptions. Bacteria 
from Bacteroidetes (~15-50%) and Firmicutes 
(~20-50%) phyla with fair deviation and to 
a lesser extent and from Actinobacteria (<5%) and 
Proteobacteria (<10%) phyla constitute the main 
taxa in the human gut; however, there is a great 
diversity at lower taxonomic levels1. Healthy con-
ditions lacking proinflammatory responses against 
commensal bacteria underlines the mutualism and 
clearly defined lines of communication between the 
microbiome and the host. Many features of the 
modern lifestyle have a direct fingerprint on the 
gut microbial profile; those include medications, 
diets high in refined carbohydrates, illness, hospi-
talization, surgery, smoking, alcohol abuse, pro-
cessed foods low in fermentable fibers, and 
chronic stress.2
Host–microbial interactions are detrimental in 
CD patients with dramatic changes at strain levels 
and reduced species richness as well as many 
defined microbial metabolites3–5 compared to non- 
IBD healthy subjects (Table 1). Some of these 
alterations are already present at the earliest stage 
in pediatric, treatment-naïve patients4,19 as well as 
in healthy first-degree relatives10 of CD patients. Of 
note, the gut microbiota of CD patients with active 
disease is comparatively more unstable over time as 
compared to CD patients with inactive disease or 
non-IBD healthy individuals.21 In these patients, 
the blooming of Proteobacteria, appearance of 
Fusobacterium, and reductions in Clostridia cluster 
IV of anaerobic bacteria are reported.1,22
Critically, many studies relate to stool samples 
but mucosal and mucus-associated microbiota has 
been recently shown to harbor consortia that are 
different from the fecal microbiota in terms of 
abundance, metabolic functioning, behavior, and 
replication.23 Thus, this makes the mucus layer of 
particular interest in CD which has not been 
exhaustively characterized. In fact, several key func-
tional pathways have been delineated being acti-
vated differently in IBD patients,24 but deep 
metagenomic and metatranscriptomic 
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investigations focusing specifically on CD are rela-
tively scarce.11 Predominant transcription of path-
ways by individual microbes within a host are 
known, and thus, loss of these organisms in CD 
can have more fare-reaching consequences than 
indicated by their genomic abundance.11 Even 
though many microbial organisms exhibited con-
cordant DNA and RNA abundances, it is also 
reported that species-specific biases in the tran-
scriptional activity reveals predominant transcrip-
tion of pathways by individual microorganisms per 
host.11 For instance, Dialister invisus is metagen-
omically present with relatively reduced abun-
dance; however, it does transcriptionally loss of 
the gene function.11 For example, all +-marked 
species in Table 1 are main producers of H2 
S through fermentation of sulfur-containing 
amino acids. Indeed, these genera have been sug-
gested to predict the severity of CD (in conjunction 
with the concomitantly observed decrease in mito-
chondrial H2S detoxification capacity).20 Overall, it 
is important to include metagenomic and 
metatranscriptomic readouts that allow us to ana-
lyze both the activity and the presence of gut micro-
organisms, which ultimately provide better insight 
into the role of the microbiome in IBD.
Besides how each community member is abun-
dant and functions in an intestinal ecological niche, 
it is important to understand their ecological roles 
which are fundamentally vital for the whole health 
biodiversity. The co-occurrence associations are 
beneficial to infer effects between taxa within the 
intestinal tract and are a key point to mechanisti-
cally examine the community structure and main-
tenance. Co-occurrence analysis by Yilmaz et al. 
revealed what could be considered as keystone spe-
cies within the ecosystem of CD patients represent-
ing the most influential taxa such as 
Faecalibacterium and Ruminococcus.1 Together 
with Lachnospira, Blautia, Dorea, Coprococcus, 
Roseburia, Oscillospira, and Bilophila, 
Faecalibacterium and Ruminococcus build up the 
most prominent and influential taxa cluster in CD 
disease groups. Alterations of taxa within this net-
work also characterize the risk of later disease 
recurrence of patients in remission after the active 
inflamed segment of CD has been surgically 
removed. The robustness of the microbial network 
as an interrelated cluster has been observed to 
associate with stable remission, whereas a loose 
structure of the microbial community and increases 
in abundance of Enterobacteriaceae is present in 
relapsing CD.25 In sum, the microbiota being pre-
sent after surgery and/or lack of reestablishing 
a healthy robust cluster seems to be emblematic 
for the susceptibility of the patient to acquire CD 
manifestation again.
One important aspect that researchers still could 
not completely resolve is whether the disruption of 
the network leading to the dysbiosis is a cause or 
consequence of inflammation in CD. Inflammation 
is able to disrupt the stability of the microbial 
composition,26 and as a matter of fact, it has been 
proposed to drive dysbiosis and bacterial invasion 
in murine models of ileal CD.27 In addition, the 
extent of dysbiosis diminishes with decreasing 
inflammation and mucosal healing due to the ben-
eficial effects of TNF inhibitors or exclusive enteral 
nutrition on patients underlining the potential 
effect of inflammation per se on the gut 
microbiota.28 However, it appears that the 
Table 1. Microbial alterations in CD patients. Relative changes 
in abundance of taxa in CD patients for Actinobacteria (A), 
Bacteroidetes (B), Firmicutes (F), Proteobacteria (P), 
Fusobacteria (Fu), and Euryarchaeota (E) phyla are categorized 
according to increases or reduction when compared to non-IBD 
subjects.
Studies Reporting Reduced Taxa in 
CD
Studies Reporting Increased Taxa in 
CD
Firmicutes (F)6–8 Bacteroidetes (B)7–9
F. prausnitzii (F) 
1,3,4,6,9–15
Bacteroidaceae (B)7





Lachnospiraceae (F)15 [Eubacterium] (F)9
Blautia (F)1,15,19 Enterobacteriaceae1
Bifidobacterium4,10,12,15,19 Bifidobacterium (A)9
Clostridium (F)1,3,8 Clostridium (F)9
Clostridia (F)8,19 Enterobacter (P)7




Erysipelotrichales (F)19 Proteobacteria (P)1,8
Dorea (F)1,19 Enterobacteriaceae (P) 
3,7,12,15,18–20
Anaerostipes3 E. coli (P) 
3,14,19
Ruminococcaceae (F)3,4,19 Pasteurellaceae (P)19
Oscillospira (F)3,9,19 Atopbobium (A)20
Christensenellaceae (F)3 +Fusobacteriales (Fu)3,12,19,20
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microbial compartment primarily and causatively 
contributes at least partly to inflammation when 
additional host factors are present since in animal 
experiments, i) dysbiotic gut microbiota can trans-
mit Crohn’s like ileitis in mice independent of fail-
ure in antimicrobial defense29 ii) IL-2 and IL-10 
deficient mice which are prone to develop colitis 
are protected when raised in germ-free 
conditions30,31 iii) susceptibility to CD is transmis-
sible by stool microbiota of CD patients was shown 
in humanized gnotobiotic mice,31 and iv) gut con-
tents elicit post-operative recurrence of CD in the 
terminal ileum proximal to the ileocolonic anasto-
mosis after ileal resection.32 Thus, it is reasonable to 
propose that dysbiosis is also linked to treatment 
failure and postoperative recurrence in CD. Even 
though it is still not certain whether or to which 
extend this link is fundamental, one can argue that 
the failure to treatment lies within the underlying 
microbiota remaining as permanent sequelae in 
refractory CD which thus, can represent 
a promising target for treatment and/or preventive 
measures.33
Long-term effects of the bacterial network dis-
ruption with increased abundance of pathobionts 
within the gut might also influence the intestinal 
hyperpermeability even in the quiescent states of 
disease without any on-going inflammation.34 
More recently and revealing, increases in intestinal 
permeability have been evidenced to determine 
later development of CD and thus, contributing to 
pathogenesis.35 The path of viable bacteria and/or 
their products such as outer membrane vesicles, 
lipopolysaccharides, peptidoglycans, muramyl- 
dipeptides, and bacterial DNA from the lumen 
through the gastrointestinal mucosa to normally 
sterile tissues, such as the mesenteric lymph nodes 
(MLN) and extra-nodal sites is referred to as bac-
terial translocation (BT).36,37 The link between dys-
biosis and inflammation can be considered to be 
any pathological increase in BT due to alterations in 
intestinal hyperpermeability (Figure 1). Numerous 
Figure 1. Interaction of microbiome, intestinal barriers, and translocating bacteria in healthy conditions and active CD. 
Eubiosis is characterized by stable cluster networks and full species richness which in concert with fully active healthy epithelial and 
secretory barriers (namely normal intestinal permeability) and normal immune responses to physiological bacterial translocation is the 
basis for stable remission. The proposed hypothetical scenario on pathophysiology of Crohn’s disease being at least partly primarily 
due to dysbiosis and loss of cluster network induced in individuals with genetic pre-disposition and/or by lifestyle/exogenous factors is 
visualized at the bottom. With increasing intestinal hyperpermeability and exaggerated pro-inflammatory immune response inflam-
mation perpetuates fueling into a vitious circle of pathological bacterial translocation and further aggravation of dysbiosis. Thus, the 
goal of treatment put forward is restoration of eubiosis being the basis for stable remission or if not achieved for recurrence.
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studies have sampled MLN of patients suffering 
from IBD and conditions requiring surgery using 
culture-dependent techniques. Pathological bac-
teria translocation (PBT) to MLN has been realized 
for long in CD.36,38 Ambrose et al. showed that 
cultured bacteria from nodes were higher in num-
bers in involved CD segments than uninvolved 
ones where these bacteria were almost absent in 
control subjects.36 Takesue and colleagues obtained 
similar trends from isolated bacteria from MLN of 
subjects (CD patients (48%) and control 
(15%))39–41
Pathological increases in BT in contrast to phy-
siological BT reflects sustained increases in quantity 
(rate and/or degree) and/or type (composition) of 
translocating agents. In that regard, as the first step 
across the epithelial layer increased adherence and 
endocytosis into enterocytes of commensal bac-
teria, particularly E. coli is observed in CD 
patients.39,42 Although any specific microorganism 
was absent in bacterial DNA positive nodes of CD 
patients or associated mucosa, Escherichia/Shigella 
(CD – 75% and healthy subjects – 60%) was 
detected at high levels in patients with DNA- 
positive lymph nodes. Of note, patients with term-
inal ileal CD had a greater proportion of E. coli.39 In 
fact, not only for E. coli but per se an increase in 
presence of adhesins and other virulence factors has 
been demonstrated in feces from CD patients.12
The follicle-associated epithelium lining Peyer’s 
patches is characterized as the site of increased 
translocation of bacteria to the underlying lym-
phoid tissue. Earliest observable lesions of recur-
rent CD are frequently microscopic erosions at the 
FAE, and an increased load of commensal bacteria 
at this vulnerable and inductive site of mucosal 
immunity has been reported in CD.42 Moreover, 
bona fide invasive pathogens, such as Salmonella 
and Shigella, are unable to invade via normal colon 
epithelial cells. However, they enter via the specia-
lized M cells which lack fuzzy glycocalyx within the 
dome epithelium overlying Peyer’s patches in the 
distal ileum and lymphoid follicles in the colon.43 
In addition, one of the most translocating bacterial 
strains is adherent-invasive E. coli (AIEC) pathovar 
which is increased in mucosa of CD patients.44 
AIEC of CD patients lacking conventional patho-
genicity genes might penetrate through M cells 
which fits well with evidence suggesting that the 
earliest lesions in CD occur at PP in the ileum and 
lymphoid follicles in the colon.45 Moreover, resi-
dent dendritic cells accumulate in an increased 
number in the subepithelial dome of Peyer’s 
patches in ileal CD and present with pronounced 
propensity to internalize translocated E. coli.46 
These E. coli also cause IL-8 to be released from 
intestinal epithelial cells and induces granuloma 
formation after internalization by cultured 
macrophages.47
Another important target site for PBT from the 
gut is the mesenteric adipose tissue when the leaky 
gut occurs in CD.48,49 BT to mesenteric adipocytes i) 
occurs at a rate similar to the translocation to MLN;50 
ii) could represent a bacterial reservoir51 iii) stimulat-
ing visceral fat for CRP-production;50 and iv) in 
terms of the microbiota profile dependent on the 
clinical status in CD patients.51 In addition, Ha 
et al. characterized the subset of mucosal-associated 
gut bacteria that consistently translocated and 
remained viable in “creeping fat” defined as an 
expansion of mesenteric adipose tissue around the 
inflamed and fibrotic intestine in CD ileal surgical 
resections.52 Translocation of C. innocuum was iden-
tified as a signature of this consortium i) with strain 
variation between mucosal and adipose isolates and 
ii) stimulating tissue remodeling via M2 macro-
phages leading to an adipose tissue barrier that serves 
to prevent systemic spread of translocated bacteria.52 
Thus, in conjunction with the well-known cytokine 
production and immune cell infiltration in adjacent 
tissue in intestinal inflammation, the mesenteric fat 
might cooperate with the gut in a proinflammatory 
feedback loop, generating a specific microbiome sig-
nature in this tissue to influence the CD status and/or 
disease progression.51,52
PBT to the systemic compartment reflected by 
detection of bacterial DNA in serum has recently 
gained much attention53,54 revealing 
Enterobacteriaceae as a major source of bacterial 
DNA53 within actively smoking CD patients harbor-
ing NOD2-, CARD15- and ATG16L1-variants.55 
Hence, these genetic risk factors for CD not only 
inhibit beneficial effects of microbial products during 
physiological BT to keep up mucosal tolerance but 
also drive pathology. PBT to the blood stream is 
evident almost twice as frequent in patients with 
clinically active disease as compared to patients 
with recurring disease.55 In fact, bacterial DNA 
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translocation was significantly and independently 
related to disease activity. In a prospective, multi-
center study on CD patients with CDAI<150, bacter-
ial DNA translocation to serum was demonstrated to 
represent an independent risk factor for relapse and 
hospitalization within 6 months.53 Potential 
mechanisms explaining the impact of BT on the 
disease activity and aggravating course of disease 
are the reported consequences of translocating bac-
terial DNA on systemic and local inflammatory 
response. Bacterial DNA in serum has been found 
to associate with increased antimicrobial peptide (β- 
defensin 2, cathelecidin LL-37) and pro- 
inflammatory cytokine levels in CD patients in 
a concentration-dependent manner.54 In addition, 
the increased proinflammatory activity in the pre-
sence of bacterial DNA translocation is particularly 
pronounced in CD patients carrying mutated var-
iants of NOD2/CARD15. Indeed, neutrophils from 
CD patients with variant NOD2-status release sig-
nificantly more TNF when exposed to E. coli DNA 
in vitro as compared to CD patients with wild-type 
NOD2 status.55 Moreover, the presence of bacterial 
DNA in serum seems to decrease the availability of 
free anti-TNF in CD patients treated with 
biologicals.55 It is tempting to speculate that this is 
caused by pronounced TNF secretion in response to 
bacterial DNA in CD with NOD2-variant genotype 
due to faster consumption of free anti-TNF.55 Thus, 
PBT in subgroups of CD patients could (at least 
partly) cause the requirement of intensified anti- 
TNF therapy.
The observation that PBT per se disrupts the 
epithelial barrier and increases intestinal 
permeability56,57 strongly indicates the perpetuating 
potency of bacterial translocation as driving force of 
a vicious cycle in CD (Figure 1). This even more 
though considering that AIEC type 1 pili-mediated 
interaction with cell-adhesion molecules abnormally 
expressed in the quiescent phase of CD may disrupt 
intestinal barrier integrity before the onset of 
inflammation.56 Accumulating evidence shows that 
pathobionts by virtue of their possession of adhesion 
mechanisms and secretion of proteases, may have 
a causative role in CD. In CD, they most likely invade 
the tissue, perhaps as a result of defective clearance by 
neutrophils and macrophages. In addition, inflamma-
tion itself and disruption of the epithelial barrier 
increases intraluminal oxygen availability which 
leads to an outgrowth of pathobionts. This example 
highlights the complex interaction between intestinal 
barrier, gut microbiota and BT which when deli-
neated in more detail will ultimately lead to improve-
ments in preventive and therapeutic measures in CD.
2. Interaction between microbiota, genetics, 
and epigenetics in CD
IBD risk genes alter the gut microbiota 
composition
As stated above, genetic risk factors influence the 
interaction between gut microbiota and mucosal 
microenvironment in CD. Genetics is a well- 
known susceptibility component for IBD develop-
ment, with more than 240 genomic IBD susceptibil-
ity loci identified in the GWAS.58 Data analyzed 
from several GWAS identified 30 CD-specific loci, 
23 UC-specific loci, and 110 loci that play a role in 
both forms of IBD.59 Interestingly, genes involved in 
the epithelial barrier function were found to be more 
associated with UC and genes engaged in cellular 
innate immunity with CD. Additionally, more than 
8% of variance in UC susceptibility and more than 
13% of the variance in CD susceptibility might be 
explained by currently identified genetic variants.60
The host genetics, similar to environmental fac-
tors, have been shown to influence the gut micro-
biome composition and diversity61 (Table 2). 
NOD2, the first IBD susceptibility gene identified, 
is a NOD-like receptor that binds bacterial mura-
myl dipeptide.72 Studies involving NOD2-deficient 
mice established that the absence of NOD2 
increases the relative abundance of Bacteroidetes 
and impairs the intestinal microbiota in several 
mouse models.73,74 Similarly, NOD2-risk allele- 
related increases in Enterobacteriaceae family was 
observed in three IBD cohorts.75
Next, ATG16L1, a gene identified by GWAS 
studies as IBD risk gene, regulates the development 
of T cells and cell autophagy.76 In mouse models, 
deletion of ATG16L1 triggers spontaneous intest-
inal inflammation with severely reduced CD4 + T 
cells.77 In ATG16L1 homozygous CD patient’s, 
enrichment of Fusobacteriaceae, Bacteroidaceae, 
Enterobacteriaceae in ileal tissue was observed as 
compared to control patients.63 Fucosyltransferase 
2 (FUT2), an enzyme that regulates intestinal 
epithelial cells-microbe interaction is another factor 
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that lost was found to increase susceptibility to CD 
development. Patients lacking functional FUT2 
alleles have abnormal mucosal barrier with 
decreased microbial diversity and changes in sev-
eral taxa.64,78 Additionally, the association between 
risk locus SLC39A8 and the abundance of 
Anaerostipes, Coprococcus, and Lachnospira was 
found in CD patients.65
Furthermore, combined genetic risk scores from 
11 functional genetic variants associated with IBD 
susceptibility were directly involved in the bacterial 
composition in the gut and were associated with 
a decrease in the abundance of butyrate-producing 
bacteria.71
Interaction between the microbiota and epige-
netics in IBD
Genetic susceptibility to develop disease might 
explain only part of disease risk and its 
heritability.79 The contribution of genetic risk 
alone to disease development was suggested to be 
around 20%.80 Epigenetic regulation of gene 
expression was proposed to play an additional role 
in the development and control of IBD.81 
According to the current definition, epigenetic 
mechanisms are all heritable alternations of gene 
expression that are caused independently of 
changes in the primary DNA sequence.81 DNA 
methylation, histones modifications modulating 
chromatin structure, microRNA interference, and 
positioning of nucleosomes are the main epigenetic 
mechanisms that control gene expression.82
DNA methylation is a process characterized by 
the covalent addition of a methyl group to 5` car-
bon of cytosines in cytosine-guanine dinucleotides 
(CpG).83 This process is catalyzed by DNA methyl-
transferases (DNMTs). DNMT1, DNMT2, 
DNMT3a, DNMT3b, and DNMT3L are five mem-
bers of DNMT protein family.84 As a result, hyper-
methylation of CpG island in promoters is 
transcriptionally repressive and genes are 
silenced.85
In addition, genes expression might be regulated 
by posttranslational histone modifications that 
include acetylation, methylation, ubiquitination, 
phosphorylation, sumoylation, and citrullination 
of histone tails.86 Acetylation is the best character-
ized process, and histone acetyl transferases 
(HATs) are the enzymes responsible for addition 
of acetyl groups to lysine residues in histones. 
Histone acetylation is associated with chromatin 
opening and transcriptional gene activity. On the 
other hand, histone deacetylation by histone dea-
cetylases (HDACs) triggers chromatin compacting 
and gene silencing.87
The epigenetic machinery is influenced by envir-
onmental factors including intestinal microbiota 
and their metabolites. The influence of bacteria on 
the epigenetic control of gene expression is well 
characterized for SCFAs, a bacterial metabolite 
formed during anaerobic fermentation of dietary 
fibers. SCFAs, namely acetate, propionate, butyrate, 
produced by Firmicutes and Bacteroides phyla, 
inhibits HDAC activity.88 Interestingly, reduced 
numbers of SCFA produces have been observed in 
IBD patients.89 There are two possible mechanisms 
of SCFA action. The first mechanism involves reg-
ulation of naïve CD4 + T cells differentiation into 
T regulatory cells (T regs). It has been shown that 
acetylation of H3 histone within Foxp3 loci that is 
required for T regs differentiation is increased by 
butyrate.88 The second mechanism involves macro-
phages, the most abundant lamina propria cells. It 
has been shown that ther production of IL-6 and 
IL-12 from lipopolysaccharide stimulated 
Table 2. Influence of IBD-associated genes on the microbial 
composition.
Gene symbol









FUT2 decreased microbial 
diversity and changes in 
several taxa
64
SLC39A8 Anaerostipes, Coprococcus, 
Lachnospira
65








BANK1, EFR3B, IL1R2, POMC Β-diversity 69
IL6 Helicobacter pylori 70
11 functional genetic variants 
in genes: NOD2, CARD9, 
ATG16L1, IRGM and FUT2




NOD2 (Nucleotide-binding Oligomerization Domain Containing protein 2), 
ATG16L1 (Autophagy-Related 16 Like 1), FUT2 (Fucosyltransferase 2), 
SLC39A8 (Solute Carrier Family 39 Member 9), CARD9 (Caspase 
Recruitment Domain Family Member 9), NLRP12 (NLR Family Pyrin 
Domain Containing 12), BANK1 (B Cell Scaffold Protein with Ankyrin 
Repeats 1), EFR3B (EFR3 Homolog B), IL1R2 (Interleukin 1 Receptor 
Type 2), POMC (proopiomelanocortin), IRGM (Immunity Related GTPase 
M), IL6 (Interleukin-6).
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macrophages was downregulated by addition of 
butyrate.90 Downregulation of proinflammatory 
cytokines produced by macrophages suggests that 
butyrate might induce hyporesponsiveness of 
macrophages and maintain tolerance in the gut.
As the epigenetic signature is profoundly cell 
specific, another cell type – intestinal epithelial 
cells (IECs), gained significant attention in studies 
focused on epigenetic regulation in relation to IBD. 
In their work on IECs from CD patients and mouse 
modes, Denizot et al. suggested that demethylation 
of CEACAM6 gene promoter in IECs correlated to 
high protein expression and favored gut inflamma-
tion mediated by colonization by AIEC. For the 
first time, due to epigenetic machinery, diet and 
the presence of methyl-donor ingredients were 
linked to the microbiota and inflammation.91
The influence of the microbiota on transcrip-
tome and DNA methylation in IECs during post-
natal development was investigated by Pan at el. 
Interestingly, differences in DNA methylation that 
are depended on the microbiota were detected early 
after birth, in contrast to transcriptome, where 
bacterial influence increased over time.92 
Moreover, authors reveal 126 genomic loci where 
the presence of the intestinal microbiota was asso-
ciated with combined differential RNA transcrip-
tion and DNA methylation. The most important 
conclusion from this study is that during develop-
ment, microbiota modulates epithelial cells tran-
scriptome and functionally methylate genes and, 
on long term, change their expression signature in 
IEC.92
In summary, epigenetic modifications connect 
genetic susceptibility with environmental factors 
via the intestinal microbiota. As epigenetic changes 
are reversible in nature, from clinical perspective, it 
is necessary to understand how it would be possible 
to control or even reverse disease associated 
changes through epigenetic mechanism.
3. Dysbiotic microbiota effect on local and 
systemic inflammation in CD
As shown, the genetic background may influence 
the microbiota composition, which, in turn, tightly 
shapes the immune pathogenic mechanisms pre-
sent in CD. During homeostasis, thus immune 
quiescence, microbial members of the commensal 
microbiota contribute to the maintenance of the 
gut barrier integrity and the optimal mucosal com-
position. They collaborate in the prevention of 
microorganisms crossing through the intestinal 
epithelium93 (Figure 2).
Regulatory T (Treg) cells interact with the 
microbiota, and their expansion is controlled by 
products of commensal bacteria,94 and their bal-
ance with adaptive Th17 cells (main productors of 
IL-17 and IL-22) and the gut microbiota is directly 
implicated in illness developing or worsening.95 As 
an example, Roseburia and taxa from 
Lachnospiraceae family are in charge of producing 
short-chain fatty acids (butyrate, acetate, and pro-
pionate) from fermentable dietary fiber as a carbon 
supply for intestinal colonocytes and differentiation 
of Tregs.88,96 Also, polysaccharide-A (PSA) of 
Bacterioides fragilis induces IL-10-expressing 
Foxp3+ Treg cells,97 and Toll-like receptor (TLR)- 
2 internalization of PSA by dendritic cells induces 
the subsequent differentiation of IL-10-producing 
Treg cells in the colon.98,99 Moreover, Roseburia 
can improve the innate response in the gut by 
inducing antimicrobial peptide production and 
increasing the gut barrier function.100 Also, 
Bacteroidetes and Lactobacillus spp. can block 
NFκB signaling pathway, reducing proinflamma-
tory microenvironment in the intestine. In vitro 
experiments using intestinal cell lines, 
Faecalibacterium prausnitzii can inhibit NFκB 
pathway through the microbial anti-inflammatory 
molecule MAM.101 Moreover, dendritic cells pro-
duction of IFN-γ and IL-12 is also downregulated 
by the presence of F. prausnitzii that promotes 
production of IL-10 in homeostatic conditions,102 
together with the expression of CD39, programmed 
death-ligand 1, and production of indoleamine 23- 
dioxygenase 1 (IDO-1) and IL-27. This dendritic 
cell phenotype can induce skewing of Th cells to 
Treg cells differentiation.101 IL-6 and TLR-4 
expression levels on dendritic cells negatively cor-
related with that of F. prausnitzii, as well as IL- 
12p40 in same cells correlated with Bacteroides 
ratio.103
As previously stated, intestinal Paneth cells can 
sense bacteria by intracellular NOD-like receptors 
(NLRs), and they exert their control through pro-
duction of antimicrobial peptides. Downregulation 
of antimicrobial peptides production may alter the 
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composition of the microbiota and lead to an 
increase in susceptibility to inflammation93 
(Figure 3). In fact, Paneth cells have a reduced 
production of α defensins in CD.104 Also, 
a reduction of mucosal-associated invariant 
T (MAIT) cells is observed in peripheral blood of 
CD, but an increase in their accumulation in intest-
inal inflamed areas. These MAIT cells can be acti-
vated by microbial-derived metabolites presented 
by dendritic cells in the context of MR-1 molecules 
and subsequently induce a proinflammatory tissue 
response.105
Moreover, the pathological variant of E. coli AIEC 
promotes Th17 differentiation in the intestine, and 
also remains functional inside macrophages, which 
elicit the release of high amount of TNF-α.106 This 
proinflammatory cytokine is also produced in a TLR- 
4 dependent way in response to Ruminococcus gnavus, 
a bacterial species related to CD among other inflam-
matory diseases.16 Also, the expression of PRRs TLR- 
5 in basolateral area of epithelium allows Clostridium 
spp. flagellin recognition, and this is one of the most 
representative antigens found in CD patients.107
As part of the innate immune response, innate 
lymphoid cell 3 (ILC3) subpopulation interacts 
with the intestinal microbiota and produces GM- 
CSF that helps maintain food tolerogenic responses 
and IL-22 that induces the production of 
Figure 2. Tolerogenic microenvironment during microbiota eubiosis in healthy intestinal tissue in Crohn’s disease. In healthy 
colonic tissue, the gut barrier is made up of a thick mucus layer containing mucin produced by Goblet cells, sIgA produced by plasma 
cells, AMPs secreted by epithelial cell, and the cellular immune system (ILCs, MAIT cells, NKTs, macrophages, dendritic cells and T cells), 
mainly organized in Peyer’s patches. DCs and macrophages produce anti-inflammatory mediators that promote iTreg Foxp3+ expan-
sion. Moreover, the eubiotic microbiota contributes to reduction of proinflammatory substrates induction (reduced activation of NFkB 
in epithelial cells) and produces SCFAs and subsequent inhibition of proinflammatory (Th1 and Th17) cell lineage activation. iTregs 
together with eubiotic microbiota are responsible of the predominant immunotolerance in intestinal tissue microenvironment, while 
ILC-derived IL-22 contributes to keep gut barrier integrity. sIgA, soluble IgA; AMPs, antimicrobial peptides; ILC, innate lymphoid cells; 
MAIT, mucosal associated invariant T cell; iNKT, invariant Natural Killer T cell; DC, dendritic cell; iTreg, induced regulatory T cells; NFkB, 
nuclear factor kappa-B; Th, T helper cell; SCFAs, short chain fatty acids, PMN, polymorphonuclear cells; TLRs, Toll-like receptors; NLRs, 
Nod-like receptors; IL, interleukin; RA, retinoic acid; TGF-β, transforming growth factor-β.
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antimicrobial peptides by epithelial cells. ILC3s 
express MHC-II that can control T CD4+ cell 
activation.108 In murine models, reduction of 
MHC-II in ILC3 induces inflammatory microbiota- 
dependent responses directed by T helper 
cells.108,109
Considering the adaptive intestinal T cell, Th 
CD4+ are highly abundant in the intestine and 
their response is mediated by crosstalk with local 
microbiota.93 Gut microbiota directs the balance of 
Th17 and Treg cells, and the altered response of 
T CD4+ to microbiota-derived antigens may give 
rise to a proinflammatory response in the intestinal 
microenvironment. Induction of Th1 and Th17 can 
be triggered by segmented filamentous bacteria in 
mice.110 These adherent bacteria can induce the 
production of IL-8/CCL20 chemokines and feed-
back the inflammatory response.111 Moreover, 
Figure 3. Immunogenic microenvironment during microbiota dysbiosis in inflamed intestinal tissue in Crohn’s disease. 
Crohn’s disease triggers induce a proinflammatory response orchestrated by tissue resident APCs activation, driving neutrophil 
recruitment, oxidative damage, the expansion of Th1 and Th17 populations and suppression of the regulatory T cell milieu. This 
environment favors the access of Tc and Trm cells to the damaged tissue. Innate lymphoid subpopulations cooperate in maintaining 
this immunogenic profile. Changes in gut microbiota composition and the reduction of SCFAs production contribute to the loss of tight 
junctions and the decrease of AMPs in the epithelial barrier, favoring an increased permeability (“leaky gut”). sIgA, soluble IgA; AMPs, 
antimicrobial peptides; ILC, innate lymphoid cells; MAIT, mucosal associated invariant T cell; iNKT, invariant Natural Killer T cell; DC, 
dendritic cell; iTreg, induced regulatory T cells; NFkB, nuclear factor kappa-B; Th, T helper cell; SCFAs, short-chain fatty acids, PMN, 
polymorphonuclear cells; TLRs, Toll-like receptors; Tc, T cytotoxic cell; NLRs, Nod-like receptors; IL, interleukin; ROs, reactive oxygen 
species; RNs, reactive nitrogen species; NETs, neutrophil extracellular traps; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-gamma; 
CCL, chemokine ligand; CCR, chemokine receptor; PBT, pathological bacterial translocation; PAMPs; pathogen-associated molecular 
patterns; AIEC, adherent invasive Escherichia coli.
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a biased microbiota-reactive Th17 response has 
been observed in IBD patients with a higher pro-
duction of IL-17A.112 Blocking of IL-17A in CD 
patients has been showed to rise disease 
symptoms.113
In the case of fungal microbiota, the 
Basidiomycota/Ascomycota ratio has been shown 
increased in the intestinal mucosa of CD patients 
with active disease.114 Furthermore, Malasezia species 
have been probed to induce the production of inflam-
matory cytokines by dendritic cells in patients carrying 
the CARD9S12N gene allele SNP, worsening colitis in 
models for CD.115 Also, antibodies recognizing 
Saccharomyces cerevisiae mannan (ASCA) have been 
detected in approximately 50% of CD patients, while 
these antibodies are measured in around 8%–20% of 
the healthy subjects.116
4. Impact of the microbiota on fibrosis in CD 
patients
While at least 10% of CD patients have a clinically 
apparent fibrostenosing phenotype at diagnosis, the 
majority of patients initially exhibits a “pure” inflam-
matory phenotype without complications (strictures 
or fistulae).117,118 In population-based studies, the rate 
of patients progressing to fibrostenosis is approxi-
mately 20% at 20 years,119 a number reaching more 
than 30% within 10 years of diagnosis in tertiary 
referral centers.117,118 The location of strictures 
seems to be determined by the segmental location of 
inflammation, the most common site being the term-
inal ileum or the ileocecal region. Strictures, however, 
can occur in any segment of the intestine, including 
the upper gastrointestinal tract.120
Concepts on the pathogenesis of intestinal fibro-
sis in IBD and especially in CD patients have sig-
nificantly changed over the last decade.121 For 
many years, intestinal strictures were seen as 
a consequence of long-standing inflammation.122 
IBD-associated intestinal wall fibrosis was seen as 
an irreversible process frequently followed by stric-
ture formations and subsequently intestinal 
obstruction requiring surgical intervention.121 
However, despite the improved control of inflam-
mation with new drugs such as biologics, the pro-
gression from inflammation to fibrosis in many CD 
patients has remained largely unaffected123 and the 
rate of surgery due to strictures remains high.124
The impact of the microbiota for tissue fibrosis 
was recognized in recent years and has been 
addressed by different experimental and clinical 
approaches. There seems to be both an impact of 
live bacteria as well as PAMPs. These microbial 
patterns, as well as “damage-associated molecular 
patterns” (DAMPs), bind or ligate to PRRs,122 
thereby triggering tissue fibrosis. Interestingly, sin-
gle-nucleotide polymorphisms affecting the func-
tion of PRRs and subsequently affecting bacterial 
sensing, recognition, or processing, such as the 
previously mentioned variants of NOD2, are asso-
ciated with fibrostenotic CD.55
Mesenchymal cells such as collagen-forming 
fibroblasts express multiple PRRs such as TLRs 
and NLRs.125 Activation of those PRRs by bacterial 
wall products, bacterial DNA,, or proteins may 
drive mesenchymal cells into differentiation into 
a profibrotic phenotype. In addition, IECs may 
undergo epithelial-to-mesenchymal transition and 
contribute to intestinal fibrosis.126 The presence of 
EMT-associated molecules was demonstrated in 
fibrotic lesions of CD patients.126
Genetic variants encoding bacterial sensing 
PRRs as well as serum antibodies against microbial 
components have been associated with the risk of 
developing intestinal fibrosis.121,125 Animal models 
do not develop intestinal fibrosis in the absence of 
a microbiota.125 In vitro data suggest a specific 
action of flagellin in the profibrogenic response of 
intestinal mesenchymal cells.
In a situation of a “leaky barrier,” translocation 
of PAMPs may occur through the gut epithelium, 
leading to the activation of subepithelial myofibro-
blasts via PRRs (e.g. TLR1 to 9 and Nod1 and −2)125 
followed by NFκB activation and expansion of 
fibroblasts (Figure 4). TLR5 ligands are known to 
induce the fibroblast cell cycle entry and prolifera-
tion and IECs undergo EMT after activation of 
TLR4.127 However, fibrosis may also occur inde-
pendent of the signaling of PRRs. In a heterotopic 
transplant mouse model of intestinal fibrosis, the 
deletion of MyD88, the adaptor protein of TLRs, 
necessary for signal transduction did not alter 
development of fibrosis. Collagen deposition and 
transforming growth factor-beta 1 (TGF-β1) 
expression was equal in MyD88+/+ and MyD88-/- 
, indicating that MyD88 was not essential for 
fibrogenesis.128
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In addition to the discussion about a potential 
pathogenic role of bacterial proteins and bacterial 
wall compounds, there is evidence for a direct effect 
of certain microbes on fibrosis formation. When mice 
are infected and colonized with Salmonella (after pre- 
disposing streptomycin treatment), edema, mucosal 
ulcerations, and severe transmural inflammation is 
known to be a consequence of this colonization. 
However, besides inflammation, significantly 
increased expression of transforming growth factor- 
B, connective tissue growth factor, and insulin-like 
growth factor-I has been detected.129 This leads to 
collagen type I deposition in the mucosa, submucosa, 
and muscularis mucosa and subsequent persistent 
intestinal wall fibrosis.129 Besides Salmonella, the CD- 
associated pathobiont entero-invasive Escherichia coli 
(EIEC) was reported to cause fibrosis in mice via 
a flagellin-dependent mechanism via IL-33 induction 
and activation of the IL-33 receptor.130 Colitis- 
susceptible IL-10-deficient mice develop fibrosis 
when monoassociated with AIEC that harbors the 
yersiniabactin (Ybt) pathogenicity island.131 
Inactivation of the Ybt siderophore production in 
AIEC nearly abrogated fibrosis.131 These findings 
may be specific for the genetic background of the 
host and the specific situation of IL-10 deficiency. 
On the other hand, it shows the impact of the micro-
biota on fibrosis development. This is further sup-
ported by the finding that the infection with chronic 
adherent-invasive E. coli in streptomycin-treated 
mouse strains (CD1, DBA/2, C3H, 129e and C57BL/ 
6) induced profibrotic growth factors and fibrosis.132 
Further evidence comes from another mouse model: 
tumor necrosis factor–like cytokine 1A (TL1A, 
TNFSF15) expression is increased in the inflamed 
gut mucosa and associated with fibrostenosing CD. 
Tl1a-overexpression in mice is followed by ileitis and 
fibrosis.133 When germ-free wild-type and Tl1a- 
transgenic mice were inoculated intragastrically with 
stool from specific pathogen–free (SPF) mice and 
a healthy human donor, the reconstitution with SPF, 
but not human microbiota, resulted in increased 
Figure 4. Intestinal fibrosis development during microbiota dysbiosis in Crohn’s disease. Mediators generated during sustained 
inflammation and continued PBT favored by gut barrier distortion induce myofibroblasts activation and extracellular matrix production 
with deposition of fibrinogen and collagen. Intestinal epithelial cells undergo EMT after activation of TLR-4 and contribute to the 
fibrotic context by inducing TGF-β. PBT, pathological bacterial translocation; TLRs, Toll-like receptors; ECM, extracellular matrix; EMT, 
epithelial to mesenchymal transition; ROs, reactive oxygen species; RNs, reactive nitrogen species; MCP-1, Monocyte Chemoattractant 
Protein-1; IL, interleukin; TGF-β, transforming growth factor-beta; SPF, Specific-pathogen-free; EIEC, Enteroinvasive Escherichia coli.
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intestinal collagen deposition and fibroblast activation 
in the Tl1a-transgenic strain.133 Microbiota strains 
that were associated with increased fibrosis in this 
mouse model were groups of mucolytic bacteria such 
as Mucispirillum schaedleri and Ruminococcus. 
Anaeroplasma were also significantly associated with 
fibrosis in the cecum of SPF-colonized mice. 
Oscillospira and Coprococcus were negatively corre-
lated with fibrosis in the cecum.133 Furthermore, simi-
lar to other models, F. prausnitzii and Bacteroides were 
negatively associated with fibrosis.133
To further elucidate the impact of the microbiota 
on the risk of intestinal stricture formation, we 
recently investigated the post-operative microbiota in 
CD patients that had already undergone resection of 
the ileo-cecal region or a segment or small intestine, 
with CD patients that had not needed an operation.1 
Parabacteroides and Clostridiales were reduced in 
inactive postsurgical patients, and Enterobacteriaceae 
were significantly and reproducibly increased.1 All 
these findings point to a specific role of host–bacteria 
interaction for intestinal fibrosis. However, further 
research will be necessary to understand the mechan-
isms behind in more detail to be able to use this 
knowledge for therapeutic interventions.
5. Microbiota modulation targeting dysbiosis 
and potential beneficial effects in CD
Once reviewed the impact of the genetic background 
and the mucosal immunity dynamic influence in 
microbiota and disease progression, exogenous factors 
must be also considered when drawing the global 
picture of gut microbiota biological interactions and 
their relevance in CD pathogenesis.
Diet has substantial influence on the microbiome, 
intestinal permeability, and development of intestinal 
inflammation.134 For instance, western diet induces 
a shift in the microbiota composition, enhancing sus-
ceptibility to AIEC infection and intestinal 
inflammation.135 Also, smoking has been detected as 
the single-most important lifestyle factor impacting on 
the gut microbiome in CD patients and represents 
a well-accepted risk factor for a more complicated 
disease course in CD.136 In addition, exercise has 
been reported to deliver health benefit to CD 
patients,137 and in terms of impact on the microbiome 
associates with taxa also represented mainly in the CD 
cluster of taxa that if reduced in abundance associates 
with worse outcome. In other words, it is tempting to 
speculate that many lifestyle factors such as diet, 
smoking and exercise mediate their impact on the 
course of CD at least partly via changes in gut micro-
biota. Vice versa a change in diet, stop smoking and 
boosting exercise may well shift the microbiome to 
eubiosis and thus, at least contribute to achieve stable 
remission in CD.
The intestinal microbiota can be also modulated in 
order to improve the inflammatory response observed 
in CD, as well as considered a potential marker for 
disease state and progression. The knowledge of spe-
cific microbial drivers of pathogenic immune 
responses is crucial for achieving an effective microbial 
therapy.138 Rebalancing the intestinal microbiota 
through the enrichment of a specific anti- 
inflammatory bacterium, such as F. prausnitzii, is 
a potential strategy for CD treatment.139 An increase 
in Bifidobacterium, Collinsella, Lachnospira, 
Lachnospiraceae, Roseburia, and Eggerthella taxa has 
been linked to a strong response to anti-TNF-α treat-
ment in CD.1 From a molecular point of view, the 
delivery of L. lactis containing a plasmid encoding for 
the anti-inflammatory molecule MAM has been 
shown effective in prevention of dinitrobenzene sul-
fonic acid-induced colitis in mice.101
Furthermore, the use of probiotics has been con-
sidered in CD. M2 macrophages, cells with immune 
anti-inflammatory properties, are induced by probio-
tic cocktail VSL#3 (four strains of Lactobacillus, three 
strains of Bifidobacterium and one of 
Streptococcus).140 This probiotic treatment helped to 
maintained remission in patients with CD.141 
Dendritic cells with tolerogenic activities (CD103+) 
can induce inhibition of Th1/Th17 immune responses 
by promoting iTreg differentiation and by producing 
different intermediaries such as TGF-β or retinoic 
acid.142 Although IL-17 production is elevated in CD 
patients, treatment with antibodies anti-IL17 has been 
shown in the past to exacerbate the disease.143 
However, microbiota products have been shown to 
ameliorate Th17 pathway, as polysaccharides from 
B. fragilis and protein fractions from F. prausnitzii 
can induce IL-10-producing Treg in mice.97
At present, fecal microbiota transplantation 
(FMT) in CD treatment is under study, with 
different clinical trials recently finished or in pro-
gress. Xiang et al. have reported clinical symp-
toms improvement in 43.7% of 174 CD patients 
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treated and clinical remission in 20.1%.144 Also, 
Sokol et al. led a randomized controlled study of 
FMT in CD patients. They did not find differ-
ences in clinical remission for FMT-treated 
patients, but they observed that the incidence of 
flare in the FMT group was lower than in the 
control group of CD patients.145 Later, Li et al. 
noticed that adult population with the second 
dose of FMT at four months of receiving first, 
achieved long-term good clinical benefits.146 
Moreover, a protocol for a double-blind, rando-
mized, placebo-controlled pilot study in CD 
pediatric population is under development (Trial 
registration number NCT03378167).147
While conclusive clinical benefits yet require 
further study, expanding data on FMT anti- 
inflammatory effects are also emerging. The ongoing 
IMPACT-Crohn study145 shows a tendency toward 
decreased circulating white blood cells in fecal versus 
sham transplanted patients. In addition, Burrello et al. 
have reported the modulation of T cell phenotypes 
and the significant reduction of pro-inflammatory 
cytokines in colonic tissue after FMT transplant in 
a murine model of DSS-induced colitis.148
6. Future perspective
The modulation of intestinal microbiota and its com-
munication with host’s regional and systemic immune 
behavior constitute a major research venue and 
a translational opportunity for improving CD out-
comes. Considering that CD progresses mainly due 
to a sustained immune dysfunction and the central 
role of microbiota dysbiosis in negatively shaping 
immune homeostasis profile, the accurate accom-
plishment of microbiota eubiosis, bearing in mind 
the genetic, epigenetic, and environmental factors, is 
of outmost relevance for disease management.
In order to come to planned interventions, it 
becomes necessary to develop a much deeper 
mechanistical understanding of the ways micro-
biota and their derivatives contribute to mucosal 
immunity and how dysbiosis modifies their cross-
talk, eventually comprising a CD pathogenesis hall-
mark. The identification of relevant specific 
bacterial metabolic pathways that may provide tar-
geted interventions, as well as new insight on 
epithelial and immune cells biology, interaction 
and response to such highly dynamic microbiome, 
should be considered in all further research efforts.
The availability and use of new sophisticated 
technologies such as in vitro systems with complex 
organoids, analysis of gene expression, and epige-
netic modifications regulating colonic tissue 
response or CRISPR-based new mutations screen-
ings, among others, will help advance in our knowl-
edge on immune mechanistic interactions with 
dysbiotic microbiota, their role in disease patho-
physiology and how to intervene on them to perso-
nalize CD management.
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